HIFU with or without immunotherapy before chemo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 70 years
- Stage II or III triple-negative breast cancer (confirmed by biopsy)
- At least one tumor that can be measured on scans
- No prior chemotherapy, immunotherapy, or radiation for breast cancer
- Good physical condition (ECOG score 0 or 1) and adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.